Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veronika Ferenc

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Langenbeck'S Archives of Surgery|March 18, 2008
Age, microbiology and prognostic scores help to differentiate between secondary and tertiary peritonitisPeter Panhofer, Barbara Izay, Markus Riedl, et al.
International Journal of Surgery (London, England)|February 4, 2014
Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo ClassificationPeter Panhofer, Veronika Ferenc, Michael Schütz, et al.
Cancer Research|February 11, 2010
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536Karoline V Gleixner, Veronika Ferenc, Barbara Peter, et al.
Blood|October 24, 2009
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugsKarl J Aichberger, Karoline V Gleixner, Irina Mirkina, et al.
Haematologica|January 19, 2011
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536Barbara Peter, Karoline V Gleixner, Sabine Cerny-Reiterer, et al.
Experimental Hematology|July 16, 2008
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalphaChristian Baumgartner, Karoline V Gleixner, Barbara Peter, et al.
Experimental Hematology|August 30, 2008
Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosisEmir Hadzijusufovic, Laura Rebuzzi, Karoline V Gleixner, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Langenbeck'S Archives of Surgery|March 18, 2008
Age, microbiology and prognostic scores help to differentiate between secondary and tertiary peritonitisPeter Panhofer, Barbara Izay, Markus Riedl, et al.
International Journal of Surgery (London, England)|February 4, 2014
Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo ClassificationPeter Panhofer, Veronika Ferenc, Michael Schütz, et al.
Cancer Research|February 11, 2010
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536Karoline V Gleixner, Veronika Ferenc, Barbara Peter, et al.
Blood|October 24, 2009
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugsKarl J Aichberger, Karoline V Gleixner, Irina Mirkina, et al.
Haematologica|January 19, 2011
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536Barbara Peter, Karoline V Gleixner, Sabine Cerny-Reiterer, et al.
Experimental Hematology|July 16, 2008
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalphaChristian Baumgartner, Karoline V Gleixner, Barbara Peter, et al.
Experimental Hematology|August 30, 2008
Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosisEmir Hadzijusufovic, Laura Rebuzzi, Karoline V Gleixner, et al.
Pageof 1